Acomplia
From Buy Acomplia
Contents |
Can Acomplia change my life? - Buy Acomplia
What is Acomplia (Rimonabant)?
|
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. The meta-analyses published today in the Lancet and BMJ reflect the data previously published, and do not introduce any new information that doctors, sanofi-aventis and regulatory bodies have not already considered and acted upon. The articles summarise the recognised benefits of Acomplia on weight and multiple risk factors, including glycaemic control in those with diabetes. Since the launch of Acomplia (Rimonabant), sanofi-aventis has worked closely to monitor safety, and in conjunction with clinicians and regulatory agencies has actively sought to ensure that treatment is safe to be used by patient.
How does Acomplia (Rimonabant) works for me?
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle. About two-thirds of Americans are overweight or obese, according to authors F Xavier Pi-Sunyer, MD, of the Obesity Research Center, St Luke's-Roosevelt Hospital, New York, and colleagues. Buy Acomplia not only if your weight problems, it will also helo you stop smoking. This excess weight greatly increases the risk of developing diabetes mellitus and heart disease and death from related causes. For this reason, researchers believe, obesity-management goals should include not only weight-loss (particularly around the waist), but also the improvement of cardio-metabolic risk factors, including abnormal cholesterol and blood sugar levels. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism. Acomplia (rimonabant) has been available in Europe since the middle of 2006, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia, so you can buy acomplia (rimonabant), it is safe to use and already tested.
What is Acomplia (Rimonabant) used for?
Acomplia (Rimonabant), just like Viagra is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. Participants receiving Acomplia, rimonabant (20 mg/day) had greater average reductions in weight, waist circumference and triglycerides, as well as a greater increase in HDL cholesterol. Participants who were switched from the higher dose of acomplia rimonabant to placebo during the second year experienced weight regain, whereas those who continued to receive 20 mg/day maintained both their weight loss and improved cardiometabolic risk factors. Buy Acomplia (Rimonabant) it is generally well tolerated, with the most common drug-related adverse event being nausea (11.2% for participants receiving rimonabant (20 mg/day). Sanofi argues that if you buy Acomplia and start the treatment, it can also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.
More about Acomplia (Rimonabant)
In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss, so you cab buy Acomplia if you want to start treatment. Acomplia is authorised in the European Union/European Economic Area, and is marketed in 13 European countries, you can buy acomplia from safely as it is proved in 2006. Buy Acomplia, Rimonabant is minimally effective in obese or overweight patients for achieving sustained weight loss. Less than one half of the patients initially enrolled in this study completed the protocol at one year. Of those remaining in the study, one fourth lost a clinically significant amount of weight, and, as with other weight loss drugs, the patients who stopped taking the medicine after one year regained the weight. Acomplia is also authorised as Zimulti, but this product is not marketed in the European Union. Before you buy Acomplia, you must know that Acomplia (rimonabant) is an anti-obesity drug, and this is the expected result of treatment. Buy Acomplia and start the treatment as obesity is now the most common nutritional disorder in western industrialised countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from consumption of fatty foods. Prevalence of obesity in the US and EU has reached epidemic levels.
